Last reviewed · How we verify
Recombinant Human Adenovirus Type 5 Injection
Recombinant Human Adenovirus Type 5 Injection is a Small molecule drug developed by Sun Yat-sen University. It is currently FDA-approved. Also known as: H101, OncorineR, Tremelimumab.
Recombinant Human Adenovirus Type 5 Injection is used in combination with systemic chemotherapy to treat various conditions, including Non Small Cell Lung Cancer and Malignant Hydrothorax. The injection is combined with endostatin and systemic chemotherapy, specifically Gemcitabine, Vinorelbine, and Paclitaxel, for treatment.
At a glance
| Generic name | Recombinant Human Adenovirus Type 5 Injection |
|---|---|
| Also known as | H101, OncorineR, Tremelimumab |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety (PHASE2)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study (PHASE2)
- Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults (PHASE1, PHASE2)
- Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention (PHASE1, PHASE2)
- Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study (PHASE2)
- Local Injection and Systemic Therapy in the Treatment of NSCLC. (PHASE2)
- Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Human Adenovirus Type 5 Injection CI brief — competitive landscape report
- Recombinant Human Adenovirus Type 5 Injection updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Recombinant Human Adenovirus Type 5 Injection
What is Recombinant Human Adenovirus Type 5 Injection?
Who makes Recombinant Human Adenovirus Type 5 Injection?
Is Recombinant Human Adenovirus Type 5 Injection also known as anything else?
What development phase is Recombinant Human Adenovirus Type 5 Injection in?
Related
- Manufacturer: Sun Yat-sen University — full pipeline
- Also known as: H101, OncorineR, Tremelimumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing